Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Derman

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Blood Advances|February 10, 2023
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myelomaBenjamin A Derman, Jeffrey Zonder, Donna Reece, et al.
Current Medical Research and Opinion|May 15, 2024
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER StudyBenjamin A Derman, Meaghan Roach, Dee Lin, et al.
Blood Cancer Journal|May 29, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplantBenjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, et al.
Journal of Hematology & Oncology|August 16, 2022
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myelomaBrian C-H Chiu, Zhou Zhang, Benjamin A Derman, et al.
Blood Advances|May 29, 2024
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapySamuel J Yates, John F Cursio, Andrew Artz, et al.
Journal for Immunotherapy of Cancer|June 22, 2022
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapiesSherin Juliet Rouhani, Jovian Yu, Daniel Olson, et al.
Hemasphere|July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myelomaOla Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Ejhaem|July 18, 2022
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adultsAnand Ashwin Patel, Joseph Heng, Emily Dworkin, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 12, 2023
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHLAlexandra E Rojek, Justin P Kline, Nicholas Feinberg, et al.
JAMA Oncology|July 21, 2022
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted StudyBenjamin A Derman, Ankit Kansagra, Jeffrey Zonder, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Blood Advances|February 10, 2023
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myelomaBenjamin A Derman, Jeffrey Zonder, Donna Reece, et al.
Current Medical Research and Opinion|May 15, 2024
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER StudyBenjamin A Derman, Meaghan Roach, Dee Lin, et al.
Blood Cancer Journal|May 29, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplantBenjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, et al.
Journal of Hematology & Oncology|August 16, 2022
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myelomaBrian C-H Chiu, Zhou Zhang, Benjamin A Derman, et al.
Blood Advances|May 29, 2024
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapySamuel J Yates, John F Cursio, Andrew Artz, et al.
Journal for Immunotherapy of Cancer|June 22, 2022
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapiesSherin Juliet Rouhani, Jovian Yu, Daniel Olson, et al.
Hemasphere|July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myelomaOla Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Ejhaem|July 18, 2022
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adultsAnand Ashwin Patel, Joseph Heng, Emily Dworkin, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 12, 2023
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHLAlexandra E Rojek, Justin P Kline, Nicholas Feinberg, et al.
JAMA Oncology|July 21, 2022
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted StudyBenjamin A Derman, Ankit Kansagra, Jeffrey Zonder, et al.
Pageof 6